Anthropic Acquires Coefficient Bio for $400 Million
AI developer Anthropic has announced the acquisition of Coefficient Bio, a New York-based biotech startup, for an estimated $400 million, reports The Information.
Founded in the previous autumn and operating predominantly under the radar, Coefficient Bio will be directly integrated into Anthropic’s healthcare life sciences division.
Although it boasts a staff of fewer than ten, Coefficient Bio has secured a remarkable valuation, largely propelled by its innovative platform that leverages artificial intelligence.
This technology is adept at mapping drug research and development, pinpointing novel drug targets, and navigating clinical regulatory strategies.
The acquisition represents a lucrative acqui-hire, affording Anthropic access to elite talent in the fiercely competitive sphere where machine learning converges with biological sciences.
Notable figures in Coefficient’s founding team include CEO Aris Theologis, a seasoned professional formerly associated with Evozyne and Paragon Biosciences, alongside CTO Nathan Frey and co-founder Samuel Stanton, both of whom have a history in machine learning with Roche’s Genentech.
Following a significant expansion of its corporate development team last year, Anthropic has actively pursued data licensing agreements and strategic acquisitions to enhance its vertical market presence.
With the integration of Coefficient Bio’s team, which will report to Anthropic’s healthcare lead Eric Kauderer-Abrams, the division aims to strengthen its relationships with pharmaceutical powerhouses such as Sanofi (NASDAQ:SNY), Novo Nordisk (NYSE:NVO), AbbVie (NYSE:ABBV), and Genmab (NASDAQ:GMAB).
Anticipating this strategic expansion, Anthropic has been diligently laying the groundwork. In October of last year, the company launched Claude Life Sciences, enhancing its primary model to interface seamlessly with industry-standard scientific tools like Benchling and BioRender.
By January, Anthropic had ventured into a HIPAA-compliant healthcare environment, introducing specialized capabilities for drafting clinical trial protocols and preparing regulatory submissions.
In light of this acquisition, major pharmaceutical companies are vigorously seeking advanced algorithms to fortify their critical infrastructure for the forthcoming generation of therapeutics.
Just last week, Eli Lilly and Company (NYSE: LLY) pledged up to $2.75 billion to further its AI-driven drug design collaboration with Insilico Medicine.
Days earlier, Earendil Labs secured $787 million in a private placement backed by Sanofi and Pfizer (NYSE: PFE) to advance its AI-generated drug pipeline, which currently includes over 40 programs.
Source link: Investingnews.com.
